Bill Welch, Phillips-Medisize The estimated number of connected medical devices – devices connected to the Internet –is expected to increase from 10 billion to 50 billion over the next decade, according to the IBM Institute for Business Value. This is due to the ability for machine-to-machine communication through cloud computing and networks of data-gathering sensors, […]
Drug-Device Combinations
Unilife files for Chapter 11 bankruptcy
Unilife (NSDQ:UNIS) filed for Chapter 11 bankruptcy today, saying it hopes to support the company’s business operations with a $7 million debtor-in-possession financing facility and its remaining cash. The cash-strapped company owes more than $22 million to Sanofi, Kahle Automation, Morgan Stanley, Hikma Pharmaceuticals and MECO Inc., according to documents that Unilife filed in the U.S. Bankruptcy […]
Tandem Diabetes launches t:connect healthcare portal
Tandem Diabetes Care (NSDQ:TNDM) launched the t:connect HCP Portal for its cloud-based t:connect diabetes management app, which integrates with the company’s touchscreen insulin pumps. Healthcare providers can now upload data from a Tandem pump and blood glucose meter simultaneously, according to Tandem. They can also find patients quickly and set patient-specific ranges to identify data that […]
Frequency raises $32m in Series A for hearing loss therapy
Frequency Therapeutics said today that it closed a $32 million Series A round, led by CoBro Ventures. Morningside Ventures, Emigrant Capital Corp., Korean Investment Partnership, Alexandria Real Estate Equities and other groups also invested in the round. The company has developed a proprietary combination of small molecule drugs that they plan to inject in the ear, […]
Adgero touts data for photodynamic drug-device combo
Adgero Biopharmaceuticals touted positive clinical data from studies of its late-stage photodynamic therapy platform for the treatment of cutaneous oncology indications, including unresectable metastatic breast cancer. The Princeton, N.J.-based company’s REM-001 therapy consists of a laser light source, a light delivery device and a photosensitizer drug. The therapy has been evaluated in 4 Phase II/III clinical […]
Bellerophon touts effects of inhaled nitric oxide in pulmonary arterial hypertension
Bellerophon Therapeutics (NSDQ:BLPH) presented data for its INOpulse nitric oxide device in patients with pulmonary arterial hypertension at the International Society of Heart and Lung Transplantation’s annual meeting. Researchers studied the effects of pulsed inhaled nitric oxide, delivered by the INOpulse device in 10 patients with pulmonary arterial hypertension both before and after exercise. The […]
Patients twice as likely to take anticoagulants with artificial intelligence platform
Researchers from the Stern Stroke Center at Montefiore Medical Center published trial results this week showing that stroke survivors were twice as likely to take anticoagulants when using an artificial intelligence platform compared to patients receiving standard therapies. The AI platform, AiCure, features software algorithms on smartphones that confirm patient identify, medication and drug ingestion. […]
Abbott to restrict Absorb bioresorbable stent in Europe
Abbott (NYSE:ABT) plans to restrict the use of its Absorb bioresorbable stent in Europe after a clinical study found a higher risk of serious adverse events. In a March 31 letter to physicians (posted online April 5 by a prominent cardiologist from Atlanta), Abbott said it would restrict use of the Absorb and Absorb GT1 devices to […]
Report: Insulin delivery devices improve adherence, lower costs
Valeritas (NSDQ:VLRX) touted data today from a publication detailing the benefits of diabetes medication delivery devices, such as the company’s V-Go insulin delivery system. The article was published in the journal Managed Care. The Bridgewater, N.J.-based company’s V-Go device is a wearable, basal-bolus insulin delivery system for patients with Type II diabetes. Patients can administer a continuous, […]
AcelRx touts data from Dsuvia pain relief trials
AcelRx Pharmaceuticals (NSDQ:ACRX) touted efficacy and safety data today for its pain reliever, Dsuvia. The company’s lead drug candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in any country. The 4 late-phase studies enrolled 480 patients total. In 2 randomized studies, enrolled patients underwent bunionectomy […]